Compare Stocks: KZR, KROS, GALT, and GLSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.06 +2.7%	$3.48	$2.03 ▼ $7.13	$201.53M	0.41	472,612 shs	66,034 shs
GLSI Greenwich LifeSciences	$14.65 +2.1%	$20.25	$7.78 ▼ $34.10	$215.06M	1.46	240,620 shs	19,865 shs
KROS Keros Therapeutics	$10.15 -1.0%	$10.66	$9.69 ▼ $22.55	$200.87M	0.99	345,570 shs	25,357 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	-1.32%	-11.80%	-33.70%	+32.89%	-16.71%
GLSI Greenwich LifeSciences	+6.03%	+6.74%	-34.75%	-37.75%	+20.23%
KROS Keros Therapeutics	+1.38%	+1.79%	-8.97%	-12.99%	-29.89%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	-1.22%	+77.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.06 +2.7%	$3.48	$2.03 ▼ $7.13	$201.53M	0.41	472,612 shs	66,034 shs
GLSI Greenwich LifeSciences	$14.65 +2.1%	$20.25	$7.78 ▼ $34.10	$215.06M	1.46	240,620 shs	19,865 shs
KROS Keros Therapeutics	$10.15 -1.0%	$10.66	$9.69 ▼ $22.55	$200.87M	0.99	345,570 shs	25,357 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	-1.32%	-11.80%	-33.70%	+32.89%	-16.71%
GLSI Greenwich LifeSciences	+6.03%	+6.74%	-34.75%	-37.75%	+20.23%
KROS Keros Therapeutics	+1.38%	+1.79%	-8.97%	-12.99%	-29.89%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	-1.22%	+77.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	1.67	Reduce	$11.00	267.89% Upside
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	296.19% Upside
KROS Keros Therapeutics	2.22	Hold	$20.50	102.27% Upside
KZR Kezar Life Sciences	1.60	Reduce	$6.00	-17.70% Downside

Current Analyst Ratings Breakdown

Latest KZR, KROS, GALT, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/23/2026	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
6/18/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/15/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/15/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
5/8/2026	KZR Kezar Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KROS Keros Therapeutics	$244.06M	0.82	$4.54 per share	2.23	$15.51 per share	0.65
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	$9.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$30.84M	-$0.41	N/A	N/A	N/A	N/A	N/A	-164.69%	8/13/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-941.15%	-368.53%	8/13/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.01	N/A	N/A	N/A	-256.60%	-19.30%	-17.91%	N/A
KZR Kezar Life Sciences	-$56.03M	-$6.17	N/A	N/A	N/A	N/A	-55.42%	-47.87%	N/A

Latest KZR, KROS, GALT, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	N/A	N/A	N/A	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A
5/15/2026	Q1 2026	GALT Galectin Therapeutics	-$0.06	-$0.08	-$0.02	-$0.08	N/A	N/A
5/14/2026	Q1 2026	KROS Keros Therapeutics	-$1.0229	-$1.21	-$0.1871	-$1.21	$1.93 million	$0.37 million
5/11/2026	Q1 2026	KZR Kezar Life Sciences	-$0.98	-$0.78	+$0.20	-$0.78	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	2.15	2.15
GLSI Greenwich LifeSciences	N/A	2.01	2.01
KROS Keros Therapeutics	N/A	22.61	22.62
KZR Kezar Life Sciences	N/A	11.52	11.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
GLSI Greenwich LifeSciences	4.16%
KROS Keros Therapeutics	71.56%
KZR Kezar Life Sciences	67.90%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	52.60%
GLSI Greenwich LifeSciences	51.47%
KROS Keros Therapeutics	12.60%
KZR Kezar Life Sciences	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
KROS Keros Therapeutics	100	19.79 million	17.30 million	Optionable
KZR Kezar Life Sciences	60	7.39 million	6.70 million	Not Optionable

KZR, KROS, GALT, and GLSI Headlines

Recent News About These Companies

KZR Share News Today

July 6, 2026 | uk.investing.com

Kezar Life Sciences Inc

May 18, 2026 | cnn.com

Kezar Life Sciences’ Risk Disclosures Rely on Cross-References, Potentially Obscuring Full Risk Picture for Investors

May 14, 2026 | theglobeandmail.com

Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair ...

April 7, 2026 | bakersfield.comB

Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

April 7, 2026 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aura Biosciences Inc (AURA) and Kezar Life Sciences (KZR)

April 1, 2026 | theglobeandmail.com

Kezar Life Sciences stock jumps on Aurinia acquisition deal

March 30, 2026 | au.investing.com

Kezar Life Sciences shares surge after Aurinia announces acquisition

March 30, 2026 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)

March 30, 2026 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

March 30, 2026 | prnewswire.com

KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders

March 30, 2026 | lasvegassun.comL

Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

March 12, 2026 | fiercebiotech.comF

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

March 12, 2026 | pharmiweb.comP

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

January 9, 2026 | businesswire.com

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

January 5, 2026 | zacks.com

Kezar Life Sciences Announces Major Workforce Reduction

November 21, 2025 | theglobeandmail.com

Kezar Life Sciences Reports Q3 2025 Financial Results

November 14, 2025 | msn.com

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

November 14, 2025 | finance.yahoo.com

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

November 7, 2025 | businesswire.com

Kezar Life Sciences (KZR) Price Target Decreased by 52.00% to 6.12

October 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, KROS, GALT, and GLSI Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$3.06 +0.08 (+2.68%)

As of 10:14 AM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Greenwich LifeSciences NASDAQ:GLSI

$14.65 +0.30 (+2.09%)

As of 10:15 AM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Keros Therapeutics NASDAQ:KROS

$10.15 -0.10 (-0.98%)

As of 10:15 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Kezar Life Sciences NASDAQ:KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, KROS, GALT, and GLSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, KROS, GALT, and GLSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, KROS, GALT, and GLSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, KROS, GALT, and GLSI Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

Keros Therapeutics NASDAQ:KROS

Kezar Life Sciences NASDAQ:KZR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, KROS, GALT, and GLSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, KROS, GALT, and GLSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, KROS, GALT, and GLSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, KROS, GALT, and GLSI Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

Keros Therapeutics NASDAQ:KROS

Kezar Life Sciences NASDAQ:KZR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools